Compare SBLX & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLX | DCOY |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 58 | 11 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 3.1M |
| IPO Year | N/A | N/A |
| Metric | SBLX | DCOY |
|---|---|---|
| Price | $2.50 | $5.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 100.8K | 14.5K |
| Earning Date | 05-13-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $0.53 |
| 52 Week High | $7.85 | $9.09 |
| Indicator | SBLX | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 45.25 |
| Support Level | $2.26 | $5.40 |
| Resistance Level | $3.05 | $6.70 |
| Average True Range (ATR) | 0.28 | 0.46 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 45.39 | 15.00 |
StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.